Clinical Trial Update: Galantamine Effects on Nicotine Responses in Smokers [Phase 1]

View source ↗

Summary

A Phase 1 trial from Yale University assessed whether galantamine modulates nicotine responses in smokers; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nicotine Dependence
• Tobacco Use Disorder

Drugs mentioned

• Galantamine (galantamine)

Snippet

Sponsor: Yale University | Conditions: Smoking, Tobacco Withdrawal | Phase 1 | Status: COMPLETED